Portal Instruments

Executive Summary

Portal Instruments is developing the PRIME platform, a needle-free drug delivery technology designed to administer high-viscosity biologics via a narrow, high-velocity stream in under a second. This approach aims to overcome the limitations of traditional injections, particularly for large-molecule drugs that require frequent self-administration. By eliminating needles and reducing injection time, the PRIME platform has the potential to improve patient comfort and adherence, addressing a critical unmet need in chronic disease management. The Cambridge, MA-based company was founded in 2012 and remains privately held, with its technology still in development. While specific financial and pipeline details are undisclosed, the platform’s ability to handle high-viscosity formulations positions it as a promising solution for the growing biologics market.

Upcoming Catalysts (preview)

• TBDPartnership with a major pharmaceutical company for co-development or licensing45% success
• TBDInitiation of a pivotal clinical trial for the PRIME platform35% success